Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 82

1.

Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.

Nozaki Y, Kato Y, Uike K, Yamamura K, Kikuchi M, Yasuda M, Ohno S, Horie M, Murayama T, Kurebayashi N, Horigome H.

Circ J. 2019 Dec 26. doi: 10.1253/circj.CJ-19-0720. [Epub ahead of print]

2.

Insights into channel modulation mechanism of RYR1 mutants using Ca2+ imaging and molecular dynamics.

Yamazawa T, Ogawa H, Murayama T, Yamaguchi M, Oyamada H, Suzuki J, Kurebayashi N, Kanemaru K, Oguchi K, Sakurai T, Iino M.

J Gen Physiol. 2020 Jan 6;152(1). pii: e201812235. doi: 10.1085/jgp.201812235.

PMID:
31841587
3.

Assays for Modulators of Ryanodine Receptor (RyR)/Ca2+ Release Channel Activity for Drug Discovery for Skeletal Muscle and Heart Diseases.

Murayama T, Kurebayashi N.

Curr Protoc Pharmacol. 2019 Dec;87(1):e71. doi: 10.1002/cpph.71.

PMID:
31834676
4.

Generation of Functional CX26-Gap-Junction-Plaque-Forming Cells with Spontaneous Ca2+ Transients via a Gap Junction Characteristic of Developing Cochlea.

Fukunaga I, Fujimoto A, Hatakeyama K, Kurebayashi N, Ikeda K, Kamiya K.

Curr Protoc Stem Cell Biol. 2019 Dec;51(1):e100. doi: 10.1002/cpsc.100.

PMID:
31756039
5.

Pilsicainide Administration Unmasks a Phenotype of Brugada Syndrome in a Patient with Overlap Syndrome due to the E1784K SCN5A Mutation.

Hasebe H, Yokoya T, Murakoshi N, Kurebayashi N.

Intern Med. 2020 Jan 1;59(1):83-87. doi: 10.2169/internalmedicine.3430-19. Epub 2019 Sep 3.

6.

Structural development of a type-1 ryanodine receptor (RyR1) Ca2+-release channel inhibitor guided by endoplasmic reticulum Ca2+ assay.

Mori S, Iinuma H, Manaka N, Ishigami-Yuasa M, Murayama T, Nishijima Y, Sakurai A, Arai R, Kurebayashi N, Sakurai T, Kagechika H.

Eur J Med Chem. 2019 Oct 1;179:837-848. doi: 10.1016/j.ejmech.2019.06.076. Epub 2019 Jun 29.

PMID:
31299492
7.

A novel strategy for treatment of cancer cachexia targeting xanthine oxidase in the brain.

Uzu M, Nonaka M, Miyano K, Sato H, Kurebayashi N, Yanagihara K, Sakurai T, Hisaka A, Uezono Y.

J Pharmacol Sci. 2019 May;140(1):109-112. doi: 10.1016/j.jphs.2019.04.005. Epub 2019 May 4.

8.

Dysfunction of muscle contraction with impaired intracellular Ca2+ handling in skeletal muscle and the effect of exercise training in male db/db mice.

Eshima H, Tamura Y, Kakehi S, Nakamura K, Kurebayashi N, Murayama T, Kakigi R, Sakurai T, Kawamori R, Watada H.

J Appl Physiol (1985). 2019 Jan 1;126(1):170-182. doi: 10.1152/japplphysiol.00048.2018. Epub 2018 Nov 15.

9.

A tryptophan residue in the caffeine-binding site of the ryanodine receptor regulates Ca2+ sensitivity.

Murayama T, Ogawa H, Kurebayashi N, Ohno S, Horie M, Sakurai T.

Commun Biol. 2018 Jul 23;1:98. doi: 10.1038/s42003-018-0103-x. eCollection 2018.

10.

Efficient High-Throughput Screening by Endoplasmic Reticulum Ca2+ Measurement to Identify Inhibitors of Ryanodine Receptor Ca2+-Release Channels.

Murayama T, Kurebayashi N, Ishigami-Yuasa M, Mori S, Suzuki Y, Akima R, Ogawa H, Suzuki J, Kanemaru K, Oyamada H, Kiuchi Y, Iino M, Kagechika H, Sakurai T.

Mol Pharmacol. 2018 Jul;94(1):722-730. doi: 10.1124/mol.117.111468. Epub 2018 Apr 19.

PMID:
29674523
11.

Therapeutic potential of ghrelin and des-acyl ghrelin against chemotherapy-induced cardiotoxicity.

Nonaka M, Kurebayashi N, Murayama T, Sugihara M, Terawaki K, Shiraishi S, Miyano K, Hosoda H, Kishida S, Kangawa K, Sakurai T, Uezono Y.

Endocr J. 2017;64(Suppl.):S35-S39. doi: 10.1507/endocrj.64.S35.

12.

Long-term, but not short-term high-fat diet induces fiber composition changes and impaired contractile force in mouse fast-twitch skeletal muscle.

Eshima H, Tamura Y, Kakehi S, Kurebayashi N, Murayama T, Nakamura K, Kakigi R, Okada T, Sakurai T, Kawamori R, Watada H.

Physiol Rep. 2017 Apr;5(7). pii: e13250. doi: 10.14814/phy2.13250.

13.

Inositol 1,4,5-trisphosphate receptor determines intracellular Ca2+ concentration in Trypanosoma cruzi throughout its life cycle.

Hashimoto M, Doi M, Kurebayashi N, Furukawa K, Hirawake-Mogi H, Ohmiya Y, Sakurai T, Mita T, Mikoshiba K, Nara T.

FEBS Open Bio. 2016 Oct 14;6(12):1178-1185. doi: 10.1002/2211-5463.12126. eCollection 2016 Dec.

14.

Extensive Ca2+ leak through K4750Q cardiac ryanodine receptors caused by cytosolic and luminal Ca2+ hypersensitivity.

Uehara A, Murayama T, Yasukochi M, Fill M, Horie M, Okamoto T, Matsuura Y, Uehara K, Fujimoto T, Sakurai T, Kurebayashi N.

J Gen Physiol. 2017 Feb;149(2):199-218. doi: 10.1085/jgp.201611624. Epub 2017 Jan 12.

15.

Effects of calcium channel blocker benidipine-based combination therapy on target blood pressure control and cardiovascular outcome: a sub-analysis of the COPE trial.

Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events (COPE) Trial Group.

Hypertens Res. 2017 Apr;40(4):376-384. doi: 10.1038/hr.2016.158. Epub 2016 Dec 1.

16.

In Vitro Models of GJB2-Related Hearing Loss Recapitulate Ca2+ Transients via a Gap Junction Characteristic of Developing Cochlea.

Fukunaga I, Fujimoto A, Hatakeyama K, Aoki T, Nishikawa A, Noda T, Minowa O, Kurebayashi N, Ikeda K, Kamiya K.

Stem Cell Reports. 2016 Dec 13;7(6):1023-1036. doi: 10.1016/j.stemcr.2016.10.005. Epub 2016 Nov 10.

17.

A type 2 ryanodine receptor variant associated with reduced Ca2+ release and short-coupled torsades de pointes ventricular arrhythmia.

Fujii Y, Itoh H, Ohno S, Murayama T, Kurebayashi N, Aoki H, Blancard M, Nakagawa Y, Yamamoto S, Matsui Y, Ichikawa M, Sonoda K, Ozawa T, Ohkubo K, Watanabe I, Guicheney P, Horie M.

Heart Rhythm. 2017 Jan;14(1):98-107. doi: 10.1016/j.hrthm.2016.10.015. Epub 2016 Oct 15.

18.

Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.

Murayama T, Kurebayashi N, Ogawa H, Yamazawa T, Oyamada H, Suzuki J, Kanemaru K, Oguchi K, Iino M, Sakurai T.

Hum Mutat. 2016 Nov;37(11):1231-1241. doi: 10.1002/humu.23072. Epub 2016 Sep 19.

PMID:
27586648
19.

Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability: post hoc analysis of the COPE trial.

Umemoto S, Ogihara T, Matsuzaki M, Rakugi H, Ohashi Y, Saruta T; Combination Therapy of Hypertension to Prevent Cardiovascular Events COPE Trial Group.

Hypertens Res. 2016 Jan;39(1):46-53. doi: 10.1038/hr.2015.104. Epub 2015 Oct 22.

20.

A dominant negative form of inositol 1,4,5-trisphosphate receptor induces metacyclogenesis and increases mitochondrial density in Trypanosoma cruzi.

Hashimoto M, Nara T, Enomoto M, Kurebayashi N, Yoshida M, Sakurai T, Mita T, Mikoshiba K.

Biochem Biophys Res Commun. 2015 Oct 23;466(3):475-80. doi: 10.1016/j.bbrc.2015.09.053. Epub 2015 Sep 12.

PMID:
26367178

Supplemental Content

Loading ...
Support Center